• Sugandha Angerish

Pharmacogenomics attempts to explore people who are susceptible to toxicity and poor response to conventional anticancer medication dosages. The therapeutic relevance of pharmacogenomics research that has already been done is still a hot subject. Though protein pharmacogenomics is well-studied in stage 1, the clinical consequences of stage II genetic diversity in enzymes or drug transporters are less well understood. The effect of pharmacokinetics, particularly the danger of some clinically variable medicinal medicines, on membrane transporters has grown in the last ten years. Polymorphisms can have diverse, sometimes even conflicting, pharmacokinetic and pharmacodynamics consequences in various cancers in response to various medicines, according to studies of different regimens and tumour types. More thorough knowledge on the various polymorphisms in drug-metabolizing enzymes and drug transporters is required for the practical use of pharmacogenomics in cancer treatment. Before personalized therapy may be used on a regular basis, a better knowledge of the intricacies of pharmacogenomics is required. This paper provides an overview on pharmacogenomics of drug transporters.

Anticancer, ABC, ATP-Binding, Drug Transporters, Pharmacogenomics.

"Pharmacogenomics of Drug Transporters: A Comprehensive Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.5, Issue 9, page no.282-286, September 2018, Available :http://www.jetir.org/papers/JETIRFH06048.pdf

"Pharmacogenomics of Drug Transporters: A Comprehensive Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.5, Issue 9, page no. pp282-286, September 2018, Available at : http://www.jetir.org/papers/JETIRFH06048.pdf